Marketed By
glenmark
Pack of
1 Injection
Salt Composition
Degarelix
Storage
Keep in cold place
₹14000₹17554.22
20.25% Off
Tax: ₹700
1
Deghor 120mg Injection
Delivering To: —
Indication
Prostate Cancer
Description
Deghor 120mg Injection is a doctor prescribed Hormone therapy based anticancer injection that is used to treat advanced prostate cancer in adult men. Deghor 120mg Injection contains 120mg of degarelix as its active salt, a synthetic GnRH receptor antagonist that blocks the gonadotropin-releasing hormone (GnRH) receptors to reduce male hormone production that drive the cancer.
Indication
Prostate Cancer
Dosage And Administration
Deghor 120mg Injection is administered subcutaneously (under the skin in the lower abdomen), depending on the cancer stage. Patients should not self-administer; it must be injected by a doctor or trained nurse. Consult a doctor for precise dosage and timing.
Mechanism Of Action
Deghor 120mg Injection contains 120mg of degarelix as its active salt, a synthetic GnRH receptor antagonist. It blocks gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland that lowers down testosterone production in the body. As a result, inhibits testosterone driven prostrate cancer.
Faqs
Deghor 120mg Injection is used to treat advanced prostate cancer in adult men.
Deghor Injection blocks gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland that lowers down testosterone production in the body. As a result, inhibits testosterone driven prostrate cancer.
No, it is not advised to self administer the Deghor Injection until and unless you yourself are not a doctor or professional, experienced health care personnel.
No, Deghor Injection is not recommended for administration during pregnancy. It causes harm to developing baby in the womb.
Yes, there are serious side effects of Deghor Injection such as severe allergic reactions, injection site reactions, heart rhythm changes etc.
References
• Persson, B. E., Kold Olesen, T., & Jensen, J. K. (2009). Degarelix: a new approach for the treatment of prostate cancer. Neuroendocrinology, 90(3), 235-244.
• Carter, N. J., & Keam, S. J. (2014). Degarelix: a review of its use in patients with prostate cancer. Drugs, 74(6), 699-712.
• Shore, N. D. (2013). Experience with degarelix in the treatment of prostate cancer. Therapeutic advances in urology, 5(1), 11-24.
• Klotz, L., Boccon‐Gibod, L., Shore, N. D., Andreou, C., Persson, B. E., Cantor, P., ... & Schröder, F. H. (2008). The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer. BJU international, 102(11), 1531-1538.
Ratings And Reviews
4.33/5
3 Ratings
5 Star
33.33%
4 Star
66.67%
3 Star
0.00%
2 Star
0.00%
1 Star
0.00%
a year ago
8 months ago
View All Reviews
Related Products
MARKETER DETAILS
glenmark
DISCLAIMER
The contents of this website are for informative purposes only. They are not deliberated to be an alternative to any professional medical prescription and treatment. Seek the advice of a qualified health provider for questions regarding the medical condition. Do not ignore any professional medical advice because of something you have read on this website. This website offers links to other websites, thereby enabling you to go to the other website directly. Therefore, Magicine Pharma isn't responsible for the content of the links in the website or links in the linked websites. The links are provided to assist the visitors and are not approved by any professional health provider.